It's rare to find diseases with large patient populations and no approved drugs. Non-alcoholic steatohepatitis (NASH) fits the bill and emerged as one of the hottest areas in pharmaceutical research in recent years. NASH, caused by ballooning obesity rates and type 2 diabetes, leads to cirrhosis and liver cancer.
Now the scary part. According to the National Institutes for Health, 10 million to 30 million people in the U.S. have NASH, and even more people have its precursor called non-alcoholic fatty liver disease. Market research firm GlobalData predicts the NASH market will exceed $18 billion by 2026.
Source: Getty Images